Thorac Cancer: Early application of EGFR-TKIs can improve the prognosis of unresectable stage III EGFR-mutant lung adenocarcinoma

Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment for advanced EGFR- mutant lung adenocarcinoma, the effect of using EGFR-TKI in unresectable stage III EGFR- mutant lung adenocarcinoma remains to be seen Explore .
Recently, a team from Taiwan, China, conducted a retrospective study to evaluate the efficacy of different treatment strategies in unresectable stage III EGFR- mutant lung adenocarcinoma .
Related results were published in Thoracic Cancer magazine .

Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment for advanced EGFR- mutant lung adenocarcinoma, the effect of using EGFR-TKI in unresectable stage III EGFR- mutant lung adenocarcinoma remains to be seen Explore .
Recently, a team from Taiwan, China, conducted a retrospective study to evaluate the efficacy of different treatment strategies in unresectable stage III EGFR- mutant lung adenocarcinoma .
Related results were published in Thoracic Cancer magazine .
Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment for advanced EGFR- mutant lung adenocarcinoma, the effect of using EGFR-TKI in unresectable stage III EGFR- mutant lung adenocarcinoma remains to be seen Explore .
The efficacy of different treatment strategies in stage III EGFR- mutant lung adenocarcinoma .
Thoracic Cancer Magazine.

The study included 2010 Nian 10 months to 2019 Nian 6 for treatment of unresectable during the month of III lung adenocarcinoma period

.

The study included 2010 Nian 10 months to 2019 Nian 6 for treatment of unresectable during the month of III lung adenocarcinoma period
.

From 2010 Nian 10 months to 2019 Nian 6 months, a total of 366 name of the new diagnosis of NSCLC patients underwent screening
.

After a median follow-up time of 22.

PFS, PFS2 and OS between groups

PFS, PFS2 and OS between groups PFS, PFS2 and OS between groups

After adjusting for possible confounding factors and using Cox proportional hazard regression analysis, the study found that in patients with EGFR-mutant adenocarcinoma, early EGFR-TKI treatment was an independent good prognostic factor compared with previous CCRT (HR 0.

33, 95%CI 0.

After adjusting for possible confounding factors and using Cox proportional hazard regression analysis, the study found that in patients with EGFR-mutant adenocarcinoma, early EGFR-TKI treatment was an independent good prognostic factor compared with previous CCRT (HR 0.

Analysis of PFS related factors

Analysis of PFS Related Factors Analysis of PFS Related Factors

In group 1 , all 10 patients received EGFR-TKIs treatment after CCRT disease progression .

When considering the time to the second objective disease progression , the PFS2 of group 2 (23.

In group 1 , all 10 patients received EGFR-TKIs treatment after CCRT disease progression .

Analysis of PFS2 related factors

Analysis of PFS2 Related Factors Analysis of PFS2 Related Factors

After adjusting for possible confounding factors in the Cox proportional hazard regression, compared with the previous use of CCRT, early use of EGFR-TKIs is an independent good prognostic factor for patients with EGFR mutations (HR 0.

34, 95% CI, 0.
13 0.

After adjusting for possible confounding factors in the Cox proportional hazard regression, compared with the previous use of CCRT, early use of EGFR-TKIs is an independent good prognostic factor for patients with EGFR mutations (HR 0.

OS related factors analysis

OS related factors analysisOS related factors analysis  OS related factors analysis           

In summary, studies have shown that EGFR-TKIs therapy is a better choice for patients with unresectable stage III EGFR mutation-positive lung adenocarcinoma

.

In summary, studies have shown that EGFR-TKIs therapy is a better choice for patients with unresectable stage III EGFR mutation-positive lung adenocarcinoma .
More clinical studies are needed to confirm this later .
In summary, studies have shown that for unresectable studies, unresectable studies have shown that EGFR-TKIs treatment is a better choice for patients with unresectable stage III EGFR mutation-positive lung adenocarcinoma .
More clinical studies are needed to confirm this later .
For patients with stage III EGFR mutation-positive lung adenocarcinoma, EGFR-TKIs treatment is a better choice
.
More clinical studies are needed to confirm this later
.

Original source:

Original source:

Wang SY, Lai CH, Chen CW, Yang SC, Chang CC, Lin CY, Yen YT, Tseng YL, Su PL, Lin CC, Su WC.
Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors.
Thorac Cancer.
2021 Nov 20.
doi: 10.
1111/1759-7714.
14237.
Epub ahead of print.
PMID: 34799993.

Wang SY, Lai CH, Chen CW, Yang SC, Chang CC, Lin CY, Yen YT, Tseng YL, Su PL, Lin CC, Su WC.
Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors.
Thorac Cancer.
2021 Nov 20.
doi: 10.
1111/1759-7714.
14237.
Epub ahead of print.
PMID: 34799993.
Leave a message here